Voyager Therapeutics’ (VYGR) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report sent to investors on Wednesday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for Voyager Therapeutics’ FY2025 earnings at ($2.03) EPS.

Several other equities analysts have also recently issued reports on the stock. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Monday, March 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $9.00 price objective (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $14.86.

Voyager Therapeutics Trading Down 4.2 %

Shares of NASDAQ:VYGR opened at $3.90 on Wednesday. The firm has a 50 day moving average of $4.88 and a 200-day moving average of $5.85. The stock has a market capitalization of $213.04 million, a PE ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a 12 month low of $3.56 and a 12 month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the prior year, the company earned $1.25 earnings per share. On average, research analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 10,778 shares of company stock worth $58,548. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics during the fourth quarter valued at approximately $29,000. Tower Research Capital LLC TRC lifted its position in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after purchasing an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management lifted its position in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the last quarter. Oxford Asset Management LLP bought a new stake in Voyager Therapeutics during the fourth quarter valued at approximately $60,000. Finally, Intech Investment Management LLC bought a new stake in Voyager Therapeutics during the third quarter valued at approximately $74,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.